TIZIANA LIFE SCIENCES LTD (0RP) - Total Liabilities
Based on the latest financial reports, TIZIANA LIFE SCIENCES LTD (0RP) has total liabilities worth €7.35 Million EUR (≈ $8.59 Million USD) as of December 2024. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Explore TIZIANA LIFE SCIENCES LTD long-term investment intensity to see how much of total assets are deployed in long-term investments.
TIZIANA LIFE SCIENCES LTD - Total Liabilities Trend (2021–2024)
This chart illustrates how TIZIANA LIFE SCIENCES LTD's total liabilities have evolved over time, based on quarterly financial data. For the complete balance sheet picture, see 0RP current and non-current assets.
TIZIANA LIFE SCIENCES LTD Competitors by Total Liabilities
The table below lists competitors of TIZIANA LIFE SCIENCES LTD ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Mahkota Group Tbk PT
JK:MGRO
|
Indonesia | Rp2.60 Trillion |
|
Mineralbrunnen Überkingen-Teinach GmbH & Co. KGaA
F:MUT
|
Germany | €74.35 Million |
|
Whitehawk Therapeutics, Inc.
NASDAQ:WHWK
|
USA | $9.85 Million |
|
São Carlos Empreendimentos e Participações S.A
SA:SCAR3
|
Brazil | R$1.79 Billion |
|
Currency Exchange International Corp
TO:CXI
|
Canada | CA$37.52 Million |
|
Basso Industry Corp
TW:1527
|
Taiwan | NT$625.95 Million |
|
HIM International Music
TWO:8446
|
Taiwan | NT$1.04 Billion |
|
Humm Group Ltd
AU:HUM
|
Australia | AU$4.54 Billion |
Liability Composition Analysis (2021–2024)
This chart breaks down TIZIANA LIFE SCIENCES LTD's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. See 0RP net asset quality score to measure how much of total assets are equity-financed.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 1.02 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 1.87 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.65 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how TIZIANA LIFE SCIENCES LTD's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for TIZIANA LIFE SCIENCES LTD (2021–2024)
The table below shows the annual total liabilities of TIZIANA LIFE SCIENCES LTD from 2021 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | €7.35 Million ≈ $8.59 Million |
+10.53% |
| 2023-12-31 | €6.65 Million ≈ $7.77 Million |
-3.74% |
| 2022-12-31 | €6.91 Million ≈ $8.07 Million |
-8.48% |
| 2021-12-31 | €7.55 Million ≈ $8.82 Million |
-- |
About TIZIANA LIFE SCIENCES LTD
Tiziana Life Sciences Ltd, a biotechnology company, engages in the development of transformative therapies for neurodegenerative and lung diseases in the United States. The company's lead product candidate in immunology is Foralumab (TZLS-401), a human anti-CD3 monoclonal antibody (mAb) for use in the treatment of Crohn's, graft versus host, ulcerative colitis, multiple sclerosis, type-1 diabetes… Read more